A marketing authorization for Zegalogue (dasiglucagon, Zealand Pharma) for the treatment of severe hypoglycemia in patients aged 6 years and older with diabetes has been recommended by the European Medicines Agency (EMA). Severe hypoglycemia is defined as having low blood glucose levels that requires assistance from another person to treat…
